Immunodeficiency Among Children with Recurrent Invasive Pneumococcal Disease

Helene Ingels, PhD,*† Lone Søebjel, PhD,‡ A.C. Lundstedt, PhD,‡ Lise Jensen, MD,‡ Inga A. Laursen, PhD,§ Lars P. Ryder, MSc,‡ Niels H.H. Heegaard, DMSc, DNBSc,§ Helle Konradsen, DMSc, * Jens Jørgen Christensen, DMSc, *‡†, Carsten Heilmann, DMSc, † and Hanne V. Marquart, PhD‡

Background: Recurrent invasive pneumococcal disease (rIPD) occurs mostly in children with an underlying disease, but some cases remain unexplained. Immune deficiency has been described in children with rIPD, but the prevalence is unknown. We used a nationwide registry of all laboratory-confirmed cases of rIPD to identify cases of unexplained rIPD and examine them for immunodeficiency.

Methods: Cases of rIPD in children 0–15 years of age from 1980 to 2008 were identified. Children without an obvious underlying disease were screened for complement function, T-cell, B-cell, natural killer–cell counts and concentration of immunoglobulins. B-cell function was evaluated by measuring antibody response to polysaccharide-based pneumococcal vaccination and the extent of fraction of somatic hypermutation. Toll-Like receptor (TLR) signaling function and mutations in key TLR-signaling molecules were examined.

Results: In total, rIPD were observed in 54 children (68 cases of rIPD of 2192 IPD cases). Children with classical risk factors for IPD were excluded, and among the remaining 22 children, 15 were eligible for analysis. Of these 6 (40%) were complement C2-deficient. Impaired vaccination response was found in 6 children of whom 3 were C2 deficient. One patient had a severe TLR signaling dysfunction. No mutations in IRAK4, IKBKG or MYD88 were found.

Conclusion: Of an unselected cohort of children with rIPD at least 11% were C2 deficient. Data suggest that screening for complement deficiencies and deficient antibody response to pneumococcal vaccines in patients with more than 1 episode of IPD is warranted.

Key Words: Streptococcus pneumoniae, complement deficiency, toll-like receptor, recurrent, immunodeficiency

Accepted for publication November 7, 2014.
From the *Department of Microbiological Surveillance and Research, National Neisseria and Streptococcus Reference Center, Statens Serum Institut, Copenhagen, Denmark; †Department of Paediatrics and Adolescent Medicine, ‡Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Denmark; §Department Clinical Biochemistry, Immunology, and Genetics, Statens Serum Institut, Copenhagen, Denmark; and †Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark.
I.A.L. is deceased.
This research was partially supported by a grant from Oda and Hans Svenningsens Foundation, Vanførefonden, Ydes foundation and Statens Serum Institut. The funding entities did not have any influence in the study design and conduct of the study; collection, management, analysis and interpretation of the data and preparation, writing, approval or decision to submit the paper for publication. The contents of the article are solely the responsibility of the authors and do not necessarily represent the official views of Statens Serum Institut or Rigshospitalet.
Address for correspondence: Helene Ingels, PhD, Department of Microbiological Surveillance and Research, The Neisseria and Streptococcus Reference Center, Statens Serum Institut, Ørestads Boulevard 5, 2300 Copenhagen, Denmark. E-mail: helene_ingels@yahoo.dk
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
ISSN: 0891-3668/15/3406-0644
DOI: 10.1097/INF.0000000000000701

S. pneumoniae is a leading cause of septicemia, pneumonia and meningitis in young children worldwide. Some children are prone to repeated episodes of invasive pneumococcal disease (IPD),1 but recurrent IPD (rIPD) is a rarity, and published reports on rIPD are limited by having few children included, selected groups of patients or short follow-up periods.2–4 Predispositions to rIPD such as acquired immunodeficiency (eg, HIV or immunodeficiency following cancer) or anatomical abnormalities (eg, cerebrospinal fluid leak, asplenia) have been reported in 40–92% of the children.2–4 Nevertheless, in some children with rIPD, the enhanced susceptibility to pneumococci is unexplained and therefore gives suspicion of underlying primary immunodeficiency.

The risk of IPD is reported to be especially high in patients with B-cell dysfunction,5–8 complement deficiencies9,10 and defects in molecules involved in the Toll-like receptor signaling pathway (TLR signaling).11–13 Complement deficiencies are rare. Individuals with complement deficiency have increased susceptibility to invasive, recurrent infections with encapsulated bacteria, such as S. pneumoniae, Neisseria meningitidis and Haemophilus influenzae.7–10 Although many studies of persons with deficiencies of the classical components of complement (C1, C2 and C4) report a predisposition to infections with S. pneumoniae, only few clinically defined groups of patients experiencing pneumococcal disease have been systematically examined for the frequency of complement deficiencies.14

In addition to deficiencies in the classical complement pathway, it has been shown that single gene mutations in key molecules (IKBKG, IRAK4 and MYD88) of the TLR signaling pathways play an important role as predisposing factor in children with rIPD.11–13 TLR deficient children may present with otherwise normal basic immunological parameters (such as immunoglobulins, T-cell, B-cell and natural killer (NK)-cell count and complement), and consequently, they can be a diagnostic challenge.

In Denmark, a nationwide study of pediatric rIPD documented that one-third of the children did not have any obvious clinical features explaining their recurrent episode.15 Here, we present results from a follow-up of this cohort. We evaluated immunological parameters including complement function, B-cell-function and TLR signaling of all eligible children.

MATERIALS AND METHODS

Study Design

A retrospective analysis was conducted using The National Streptococcus pneumoniae Register, which contains nationwide laboratory-confirmed data from IPD cases in Denmark since 1938. Bacterial isolates are submitted routinely from all departments of clinical microbiology to the Neisseria and Streptococcus Reference Center at Statens Serum Institut. Children aged 0–15 years with a laboratory-confirmed case of IPD during January 1980–December 2008 were identified as previously described.15 Recurrent episodes of IPD were defined as isolation of S. pneumoniae from any
normally sterile site ≥30 days after initial positive culture or ≤30 days if the recurrent infection was with a new pneumococcal serotype. In Denmark, pneumococcal conjugate vaccination was introduced in the infant immunization program in October 2007. One of the included children (patient 12) received this vaccination as part of the vaccine program before the first rIPD episode.

Follow-Up
Clinical data were obtained from hospital records and from The National Register of Patients (Landspatientregistret). The following data were collected: sex, age, background disease, localization of infection, data on vaccination and outcome. Children without a background disease known to predispose to IPD (such as acquired immunodeficiency or anatomical abnormalities) were invited to participate in an investigation study by having a blood sample taken and screened for abnormalities in basic immunological parameters and B-cell and TLR signaling function (Fig. 1). In cases with a family history of infections, all close relatives (parents, siblings and grandparents) were invited to be tested for abnormalities in basic immunological parameters.

Blood Samples
Blood samples were taken from children with rIPD, healthy adult blood donors and healthy children (aged 0.25–8.0 years, sex distribution: 7 girls and 5 boys) after informed consent was obtained.

Complement Analysis
Screening of the classical, alternative and lectin complement pathways was performed using a commercially available solid-phase assay (Wielisa) as recommended by the manufacturer (Wieslab, Malmö, Sweden). Detection of individual complement components were performed in patients with reduced complement activation, using rocket immunoelectrophoresis as previously described. Cases with suspected complement C2 deficiency were genetically confirmed by investigation for the 28 base pair genomic deletion. Mannan binding lectin genotypes were determined.

B-Cell Function

Pneumococcal Antibody Determination

In patients vaccinated with the 23-valent pneumococcal polysaccharide vaccine (pneumovax 23 Merck; PPV23), data on the serotype-specific IgG response were accessed retrospectively. In a standardized enzyme-linked immunosorbent assay, concentrations of antibodies against 6 serotypes: 1, 4, 7F, 14, 18C and 19F, and a geometric mean for all 6 serotypes combined were determined.

Somatic Hypermutation
To examine the level of affinity maturation of antibodies, somatic hypermutation (SHM) in κ-light-chain transcripts was assessed using a VKA27–specific restriction enzyme-based hot-spot mutation assay as previously described.

Functional Assay for TLR Signaling

Every analysis of a patient sample was compared with 2 simultaneously analyzed healthy controls, and the result considered low if below 50% of the lowest control.

TLR Signaling Monitored by Analysis of CD62L Shedding

Whole blood was stimulated as previously described, with little modification in relation to the used agonists. For each stimulation, 100 μL heparinized blood was treated with Polymyxin B, 10 μg/mL for 20 minutes (except the sample stimulated with lipopolysaccharide) and hereafter, incubated at 37°C in a 5% CO2 atmosphere for 1 hour with the individual agonists Pam3csk4 (Invivogen, San Francisco, CA; TLR1/2), Pam2csk4 (Invivogen; TLR2/6), lipopolysaccharide (Invivogen; TLR4), flagellin-ST (Invivogen; TLR5), CL097 (Invivogen; TLR7/8), ssRNA40 (LyoVec, Invivogen; TLR8) and with poly-N-acetyl-glucosamine and poly-N-acetyl-glucosamine in A (Sigma-Aldrich, St. Louis, MO) or tumor necrosis factors a (TNFa; R&D Systems, Minneapolis, MN) as positive controls. After activation, the erythrocytes were lysed in EasyLyse (Dako) and washed twice in phosphate-buffered saline. The cells were incubated with anti-human CD62L or isotype control (BD Biosciences, Beckman Coulter, Miami, Florida) and analyzed on a Beckman Coulter-FC500 flow cytometer.

All samples, except 1 (Table 2, patient 13) were collected during an infection-free interval. The blood was analyzed as soon as possible and always within 16 hours. The healthy adult blood donors and healthy children were used as controls in the TLR signaling assay.
TLR Signaling Monitored by Analysis of Cytokine Production

Human peripheral blood mononuclear cells were isolated by Lymphoprep density gradient centrifugation according to the manufacturer’s instructions (Nycom A/S, Nycom, Oslo, Norway). Peripheral blood mononuclear cells were stimulated in duplicates with TLR 1–2 and 4–8 agonists as described above and incubated at 37°C in a 5% CO2 atmosphere for 24 hours. After incubation, the supernatant was analyzed for the presence of IL-6 and TNFα using a Multiplex Bead-based Luminex assay.27

TLR Genetics

All boys were screened for mutations in IKBKG [NF–kappa B Essential Modulator (NEMO)] and all included patients for mutations in IRAK4 and MYD88. Sequencing was done with BigDye technology (Big Dye Terminator sequencing kit 3.1; PE Applied Biosystems, Foster City, CA) and included the coding exons and consensus splice sites.

Statistics

Cytokine production between groups was compared using Student’s t-test or 1 way analysis of variance, a P-value less than 0.05 was considered significant.

Ethical Approval

The study was approved by the Danish Data Protection Agency (j.nr. 2007-41-1407) and the local Ethics Committee (j.nr HB-2008–094).

RESULTS

Identification of Children with rIPD

Over the 29-year study period, 2192 children were diagnosed with IPD. Among the 2128 children surviving, their first episode of IPD recurrent infection was reported in 54 children. Clinical data from hospital journals were reviewed in these 54 children, and in 32 children, a clinical feature (stem cell transplantation, anatomical

| Patient | Episode of IPD | Pneumococcal Serotype | Age at episode of IPD | Other Clinical Features | Family History of Infections | Age at Sampling (years) | Age at Diagnosis (years) | Diagnoses |
|---------|----------------|------------------------|-----------------------|-------------------------|-----------------------------|-------------------------|--------------------------|-----------|
| 1       | Meningitis     | 38                     | 5 mo                  | Age 0–6 yrs: Otitis, failure to thrive; Age 7–14 yrs: Frequent URT; Sequelae: unilateral deafness | Yes | 27 | 4 | Complement C2 deficiency |
| 2       | Meningitis     | 4, 14                  | 2 yrs 2 yrs 2 yrs 11 mo | Frequent URTI | Yes | 10 | 3 | Complement C2 deficiency |
| 3       | Bacteremia     | 9V                     | 11 mo 12 mo 2 yrs     | 12 days old: febrile episode with high CRP | Yes | 4 | 3 | Complement C2 deficiency |
| 4       | Bacteremia     | 6F                     | 2 mo 2 yrs 5 mo 2 yrs | 15 days old: febrile episode with high CRP; Joint symptoms, unspecific | Yes | 4 | 3 | Complement C2 deficiency |
| 5       | Bacteremia     | 12F, 4                 | 6 yrs 6 yrs 1 mo 10 mo | Age 0–6: sinusitis, tonsillitis; Age 6: tonsillectomy; Age 6+: no increased morbidity | No | 17 | 17 | Complement C2 deficiency |
| 6       | Bacteremia     | 6B, 34                 | 11 mo 6 yrs 2 yrs 2 yrs | Age 0–6: common febrile episodes of unknown origin; Age 7–14: prone to URTI, sinusitis | No | 12 | 12 | Complement C2 deficiency |
| 7       | Bacteremia     | 6B, 6B                 | 11 mo 13 mo 8 mo 11 mo | Prone to otitis | No | 2 | 2 | No underlying condition found |
| 8       | Bacteremia     | 23F, 9N                | 11 mo 7 mo 8 mo 6 yrs | Prone to otitis | No | 4 | 4 | SAD toward pneumococcal polysaccharides |
| 9       | Bacteremia     | 12F, 4                 | 11 mo 11 mo 1 wk     | | No | | | No underlying condition found |
| 10      | Meningitis     | 11A                    | 3 yrs 6 yrs 1 mo 3 yrs | Meningitis × 7–8 (various agents) | No | 7 | | No underlying condition found |
| 11      | Meningitis     | 18C                    | 2 yrs 6 yrs 2 yrs 7 yrs | Pneumococcal endocarditis with cerebral embolia | No | 17 | | No underlying condition found |
| 12      | Meningitis     | 11A                    | 3 yrs 10 wks 5 mo 10 wks | | No | 1 | | No underlying condition found |
| 13      | Bacteremia     | 19F                    | 19F 11F 1F 5 mo 15 mo | | No | 2 | 2 | | Toll-like receptor defect |
| 14      | Meningitis     | 18C                    | 18C 6 mo 6 mo 6 mo 18C | Frequent URTI | Yes | 6 | 6 | SAD toward; pneumococcal polysaccharides |
| 15      | Bacteremia     | 6B                     | 15 mo 8 mo 13 mo 15 mo | Prone to otitis, conjunctivitis | Yes | 4 | 4 | SAD toward Pneumococcal polysaccharides |

URTI indicates upper respiratory tract infections, CRP, C-reactive protein, GBS, group B Streptococcus.
TABLE 2  Immunological Profile of Children Experiencing Recurrent Invasive Pneumococcal Disease

| Patient | Complement Pathway | MBL Genotype | Somatic Hypermutation | Specific IgG Response to Pneumococcal Polysaccharides | TLR Functional Assay | TLR Cytokine Response |
|---------|--------------------|--------------|-----------------------|-------------------------------------------------------|----------------------|----------------------|
| 1       | C2 def             | YA/YA*       | Normal                | Normal                                                | Normal               | Normal               |
| 2       | C2 def             | YA/YA*       | Normal                | Normal                                                | Preactivated         | Normal               |
| 3       | C2 def             | YA/YA*       | Normal                | Normal                                                | Not done             | Normal               |
| 4       | C2 def             | YA/YA*       | Normal                | Impaired                                              | Not done             | Normal               |
| 5       | C2 def             | XB/Da        | Reduced               | Impaired                                              | Normal               | Normal               |
| 6       | C2 def             | YA/YA*       | Subnormal             | Impaired                                              | Normal               | Normal               |
| 7       | Normal             | YA/YA*       | Normal                | Normal                                                | Not done             | Reduced              |
| 8       | Normal             | YA/XA*       | —                     | Impaired                                              | Preactivated         | Normal               |
| 9       | Normal             | YA/B†        | —                     | Not vaccinated                                        | Normal               | Normal               |
| 10      | Normal             | YA/XA†       | Normal                | Not vaccinated                                        | Normal               | Normal               |
| 11      | Normal             | YA/YA*       | Normal                | Not vaccinated                                        | Normal               | Normal               |
| 12      | Normal             | YA/YA*       | Normal                | Not done                                              | Normal               | Normal               |
| 13      | Normal             | XA/D†        | Normal                | Impaired                                              | Impaired             | Low††                |
| 14      | Normal             | YA/D†        | normal                | Impaired                                              | Normal               | Normal               |
| 15      | Normal             | YA/YA*       | Normal                | Impaired                                              | Normal               | Normal               |

Functional test for somatic hypermutation in the rearranged immunoglobulin genes of B-cells (27), Em-dash indicates information not available because of lack of material.

*MBL genotype associated with high MBL level.
†MBL genotype associated with reduced MBL level.
‡MBL genotype associated with much reduced MBL level.
§MBL genotype associated with no functional MBL level.
¶SHM of 6.9%, age at blood sampling: 17 years.
║SHM of 14.8%, age at blood sampling: 12 years.
**This patient was vaccinated with the pneumococcal conjugate vaccine (PCV7) and not the polysaccharide based vaccine (PPV23).
††The blood sample for the TLR cytokine assay could not be obtained during an infection free interval because of chronic mycobacterial infection. This patient had generally a low TNF response but responded with IL-6, however, reduced (more details in Fig. 2).
MBL indicates mannan binding lectin.

FIGURE 2. CD62L shedding upon TLR stimulation with 6 agonists (and the polymyxin A positive control) in 2 persons: a healthy control and a TLR signaling deficient patient. TLR stimulation was analyzed by flow cytometry. The receptor expression on granulocytes before (red) and after (green) is presented. The results are presented as histograms of events gated on granulocytes in a sideward scatter/forward scatter diagram.
defects, renal disease, etc.) predisposing to rIPD was documented. The remaining 22 children were invited to participate in a further immunologic follow-up. Among the 22 children with no obvious underlying diseases, 1 child died before follow-up, and 6 children did not wish to participate in the study. The remaining 15 patients and their families (if positive family history) were included in the immunological follow-up investigation (Fig. 1).

The average age of study subjects when blood was assessed was 12.7 years (median: 6.2, range 2.1—36 years), sex distribution: 7 girls and 8 boys, and the mean time between the first episode of rIPD and the immunological evaluation was 6 years (range 0.5–20 years).

Complement Function and Standard Immunological Parameters

All children had T-cell, B-cell and NK-cell counts within normal ranges. Furthermore, immunoglobulin levels including IgG-subclasses were within normal ranges as defined by age-matched controls.

We found 6 cases of C2 deficiency among the 15 children (40%) (Fig. 1, Table 1). Four patients were diagnosed with C2 deficiency at the initial clinical investigation following rIPD, and 2 were diagnosed in our investigational follow-up because a functional screen of the complement pathway was not included in the initial clinical evaluation. All patients with reduced complement activation were identified as C2 deficient and confirmed genetically. No other complement deficiencies were found. Among the C2 deficient patients, 2 also had a reduced activation of the lectin pathway (Table 2).

B-Cell Function

Of the 15 children, 12 were vaccinated with the PPV23, and of these, 6 (50%) responded insufficiently to vaccination despite normal ranges of immunoglobulins. The nonresponders comprised 3 children with C2 deficiency and 3 children with no other immunological abnormalities (Tables 1 and 2).

Two of the 3 C2 deficient patients with impaired vaccination response had a reduced fraction of SHM in their B cells indicating a fundamental B cell dysfunction (Table 2).

The last 3 children, all boys, with an impaired PPV23 vaccination response fulfilled the criteria of the diagnosis: specific antibody deficiency (SAD) toward pneumococcal polysaccharides. Two of the children with SAD had a family history of infections, 1 (Tables 1 and 2, patient 14) had 2 brothers with repetitive episodes of upper respiratory tract infection and 1 healthy sister. All 3 brothers had an impaired response to PPV23 vaccination for all 6 tested pneumococcal serotypes. Family members, including parents and grandparents on both sides were tested for abnormalities in standard immunological

FIGURE 3 Cytokine production upon TLR stimulation with 6 agonists in (1) children with recurrent IPD, (2) healthy adults (controls), (3) healthy children (controls) and (4) family members to children with recurrent IPD. Diamond formed dot: child with a defective response in the CD62L shedding assay (patient 13). Star-shaped dot indicates child with specific antibody deficiency to pneumococcal polysaccharides (patient 15). Triangle dot indicates child with Complement C2 def. (patient 6). Squared dot indicates child with complement C2 def. (patient 5).
parameters, and as in the index child, none were found. Another child (Tables 1 and 2, patient 15) had a brother and a mother with repetitive pneumonic episodes in the first 2 years of life (>8 episodes/Year). Family members including parents and grandparents were tested and found negative for abnormalities in standard immunological parameters. Of note, it was not possible to test the specific IgG response to PPV23 vaccination of family members in this family.

**TLR Signaling Function**

TLR signaling was determined for the 15 children with rIPD and 6 family members. Because of sample transportation times in excess of 6 hours 4 blood samples were not eligible for the CD62L shedding assay. One child, a boy, who experienced 4 episodes of pneumococcal bacteremia in his first 3 years of life, had a severely reduced response to all 6 used TLR agonists in the CD62L shedding assay, with an adequate response to the positive control (polymyxin A; Fig. 2). When his cytokine responses to the 6 used TLR agonists were evaluated, his TNFa response was below unstimulated controls (Figs. 3 and 4). All his IL6 responses were reduced but not absent. No mutations in \( IRAK4 \), \( IKBKG \) (NEMO) or \( MYD88 \) were found.

In addition, 2 other patients were suspected for reduced TNFa and IL6 responses upon TLR stimulation, and the analyses were repeated on a fresh blood sample. In one of these patients reduced TNFa and IL6 responses to TLR stimulation were confirmed (when compared with 2 simultaneously studied healthy controls, reduced TNFa response to 4 of 6 agonists and reduced IL6 response to 5 of 6 agonists was found; Fig. 4). The remaining cohort of patients with rIPD had normal TLR signaling function as evaluated by the CD62L shedding and cytokine assays (Fig. 3). We screened all boys for mutations in IKBKG (NEMO), and we

![Figure 4](image-url)

**FIGURE 4** Cytokine production upon TLR stimulation with 6 agonists. Two patients presented responses with reduced/absent levels of cytokines upon TLR stimulation.
examined all patients for mutations in IRAK4 and MYD88. None of these mutations were found.

**DISCUSSION**

In this nationwide follow-up study of pediatric rIPD, we found a surprisingly high prevalence (211%) of C2 deficient children, and among 15 children experiencing rIPD without obvious underlying disease, 40% were C2 deficient. In the background population, the incidence of C2 deficiency is about 1:20,000. An additional important finding was the identification of 3 children with a selective antibody deficiency toward pneumococcal polysaccharides and 1 child with a severe TLR signaling dysfunction.

Delayed diagnosis of complement deficiency can be associated with increased morbidity and mortality; therefore, it is of clinical importance that persons with C2 deficiency and recurrent infections are identified. Two of the C2 deficient patients in our cohort were diagnosed late, despite having experienced 2 invasive bacterial infections and frequent episodes of upper respiratory tract infections. This finding agrees with a recent study of 22 complement-deficient patients, which reported a median delay of 56 months (range 0–136) from the initial symptoms until diagnosis.

The high incidence of C2 deficiency in our cohort highlights the importance of an intact complement function in the host defense against *S. pneumonia* and underlines the relevance of complement screening in individuals with rIPD. It is important to perform a functional testing of the complement pathways to detect C2 deficiency. C3 and C4 measurements alone cannot exclude complement deficiency.

Among the 6 C2 deficient children, 3 responded insufficiently to the 23-valent pneumococcal vaccine. Reduced vaccination response in some, but not all, complement deficient persons is previously reported. Complement is involved in antigen-driven immune activation presentation explaining why a deficiency may lead to impaired vaccination response. Two of the C2 deficient children with impaired vaccination response had a reduced fraction of SHM in their B cells. This reduced capability to produce high-avidity immunoglobulins could be a part of the explanation why some C2 deficient persons lack adequate vaccine responses and are more prone to infections than others.

We diagnosed 3 children with a selective antibody deficiency toward pneumococcal polysaccharides (SAD). Apart from being a normal phenomenon in children under 2 years, SAD is commonly reported in certain groups of children with repetitive respiratory infections including acute otitis media. Children that do not respond to PPV23 may reach sufficient antibody levels when given pneumococcal conjugate vaccine indicating normal T-cell-dependent B-cell immunity.

Children with defective TLR signaling (IRAK-4 and MyD88 deficiencies) present with a narrow phenotype with recurrent invasive pyogenic bacterial infection. Mutations in the X-linked NEMO gene cause impaired NF-κB-mediated cellular responses to multiple receptors and therefore confer a broader predisposition to infections. Together, these disorders have now been diagnosed in around 150 patients worldwide but always in highly selected groups. We investigated TLR signaling in a population-based child cohort and found 1 child with severely impaired functional TLR stimulation deficiency in the CD62L shedding assay, absent TNFα response and reduced IL-6 response. Specific hypomorphic variants of NEMO are associated with distinct phenotypes, and certain patients with NEMO deficiency exhibit varying degrees of impaired TLR signaling often thought to lead to the susceptibility of these patients to mycobacteria and other pathogens. It may, therefore, be speculated that our patient with impaired TLR function, despite the fact that we have not detected specific mutations or deletions in the NEMO gene, might suffer from an indirectly impaired but clinical important NEMO dysfunction. The more moderately reduced but not absent TNFα and IL6 response to TLR stimulation observed in another patient may be caused by modifying polymorphisms in the TLRs or in molecules involved in their signaling pathways.

To our knowledge, a study of prevalence of TLR defects in a larger population of unselected children with a clinical narrow phenotype has not been carried out. Our study confirms that TLR signaling defects exist as a predisposing factor to rIPD in children but underline that other primary immune deficiencies are more frequent in a Danish setting. Taking into consideration the high proportion of rIPD children with recognized anatomical etiology one may speculate whether some of the unexplained rIPD cases may in fact have an underlying unrecognized, eg, functional hypoplasminism, which notoriously is very difficult to diagnose in due time. Furthermore, as the narrow spectrum of the infection susceptibility resembles the pattern of pathogen specific immunodeficiencies resulting from mutations in the innate immune system, one may speculate if hitherto unknown mechanisms may be suffering. Our findings confirm the notion that 2 invasive infectious episodes, in the absence of background disease knowing to predispose to IPD, is a major pointer toward the presence of primary immune deficiencies.

**ACKNOWLEDGMENTS**

The authors gratefully acknowledge the Danish Departments of Clinical Microbiology for submitting invasive pneumococcal isolates for national surveillance and all the pediatric departments in Denmark allowing access to their patient files. The dedicated staffs at the department of clinical immunology are thanked for their skilled laboratory work. Finally, a very large thanks to the families and children willing to participate in the study.

**REFERENCES**

1. Hjuler T, Wohlfahrt J, Staum Kaltoft M, et al. Risks of invasive pneumococcal disease in children with underlying chronic diseases. *Pediatrics*. 2008;122:e26–e32.
2. Orlicek SL, Herrod HG, Leggiadro RJ, et al. Repeated invasive pneumococcal infections in young children without apparent underlying immunodeficiency. *J Pediatr*. 1997;130:284–288.
3. Venetz I, Schopfer K, Muhlemann K. Paediatric invasive pneumococcal disease in Switzerland, 1985–1994. *Int J Epidemiol*. 1998;27:1101–1114.
4. King MD, Whitney CG, Parekh F, et al; Active Bacterial Core Surveillance Team/Emerging Infections Program Network. Recurrent invasive pneumococcal disease: a population-based assessment. *Clin Infect Dis*. 2003;37:1029–1036.
5. Einarsdottir HM, Erlendsdottir H, Kristinsson KG, et al. Nationwide study of recurrent invasive pneumococcal infections in a population with a low prevalence of human immunodeficiency virus infection. *Clin Microbiol Infect*. 2005;11:744–749.
6. Mason EO Jr, Wald ER, Tan TQ, et al. Recurrent systemic pneumococcal disease in children. *Pediatr Infect Dis J*. 2007;26:480–484.
7. Resnick ES, Moshier EL, Godbold JH, et al. Morbidity and mortality in common variable immune deficiency over 4 decades. *Blood*. 2012;119:1650–1657.
8. Oksenhendler E, Gérard L, Fieschi C, et al; DEFI Study Group. Infections causing polymorphisms in the TLRs or in molecules involved in their signaling. *Int J Epidemiol*. 2007;75:1545–1555.
9. Carneiro-Sampaio M, Coutinho A. Immunity to microbes: lessons from primary immunodeficiencies. *Infect Immun*. 2007;75:1545–1555.
10. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. *Clin Microbiol Rev*. 2010;23:740–780.
11. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. *Science*. 2003;299:2076–2079.

© 2015 Wolters Kluwer Health, Inc. All rights reserved.
12. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science. 2008;321:691–696.

13. Ku CL, Picard C, Erdös M, et al. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet. 2007;44:16–23.

14. Ekdahl K, Truedsson L, Sjöholm AG, et al. Complete analysis of adult patients with a history of bacteremic pneumococcal infections or recurrent pneumonia. Scand J Infect Dis. 1995;27:111–117.

15. Ingels H, Lambertsen L, Harboe ZB, et al. Recurrent invasive pneumococcal disease in children: epidemiological, microbiological and clinical aspects from a Danish 3-year nationwide survey (1980–2013). Scand J Infect Dis. 2014;46:265–271.

16. Seelen MA, Roos A, Wieslander J, et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. 2005;296:187–198.

17. Johnson U, Truedsson L, Gustavii B. Complement components in 100 newborns and their mothers determined by electroimmunoassay. Acta Pathol Microbiol Immunol Scand C. 1983;91:147–150.

18. Johnson CA, Densen P, Hurford RK Jr, et al. Type I human complement C2 deficiency. A 28-base pair gene deletion causes skipping of exon 6 during RNA splicing. J Biol Chem. 1992;267:9347–9353.

19. Garrel P, J Strom J, Quist L, et al. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis. 2003;188:1394–1403.

20. Konradsen HB, Sørensen UB, Henrichsen J. A modified enzyme-linked immunosorbent assay for measuring type-specific anti-pneumococcal capsular polysaccharide antibodies. J Immunol Methods. 1993;164:13–20.

21. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis. 1995;21:616–620.

22. Sørensen RU, Leiva LE, Javier FC 3rd, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. 1998;102:215–221.

23. Boyle RJ, Le C, Balloch A, et al. The clinical syndrome of specific antibody deficiency in children. Clin Exp Immunol. 2006;146:486–492.

24. Sorensen RU, Hidalgo H, Moore C, et al. Post-immunization pneumococcal antibody titers and IgG subclasses. Pediatr Pulmonol. 1996;22:167–173.

25. Andersen P, Permin H, Andersen V, et al. Deficiency of somatic hypermutation of the antibody light chain is associated with increased frequency of severe respiratory tract infection in common variable immunodeficiency. Blood. 2005;105:511–517.

26. von Bernuth H, Ku CL, Rodriguez-Galleco C, et al. A fast procedure for the detection of defects in Toll-like receptor signaling. Pediatrics. 2006;118:2498–2503.

27. Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med. 2007;204:2407–2422.

28. Geha RS, Notarangelo LD, Casanova JL, et al; International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol. 2007;120:776–794.

29. Sjöholm AG, Jönsson G, Brasconier JH, et al. Complement deficiency and disease: an update. Mol Immunol. 2006;43:78–85.

30. Subbarayan A, Colarussi G, Hughes SM et al. Clinical features that identify children with primary immunodeficiency diseases. Pediatrics. 2011;127:810–816.

31. Jönsson G, Lood C, Gullstrand B, et al. Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation. Clin Immunol. 2012;144:214–227.

32. Andreoni J, Käyhty H, Densen P. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in low complement-component-deficient individuals. J Infect Dis. 1993;168:227–231.

33. Attwood JT, Williams Y, Feighery C. Impaired IgG responses in a child with homozygous C2 deficiency and recurrent pneumococcal septicactemia. Acta Paediatr. 2001;90:99–101.

34. Carter RH, Fearon DT. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM. J Immunol. 1989;143:1755–1760.

35. Ochs HD, Nonoyama S, Zhu Q, et al. Regulation of antibody responses: the role of complement and adhesion molecules. Clin Immunol. Immunopathol. 1993;67:S33–S40.

36. Dempsey PW, Allison ME, Akkaraju S, et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271:348–350.

37. Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J. 1998;17:685–691.

38. Barnett ED, Pelton SI, Cabral HJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis. 1999;29:191–192.

39. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBβ deficiency. Clin Microbiol Rev. 2011;24:490–497.

40. Hansson EP, Monaco-Shawver L, Solt LA, et al. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol. 2006;122:1169–1177.e16.

41. Deering RP, Orange JS. Development of a clinical assay to evaluate toll-like receptor function. Clin Vaccine Immunol. 2006;13:68–76.

42. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond). 2008;114:347–360.

43. Angelaki CL, McKay E, Blackie B. A case of functional asplenia and pneumococcal sepsis. Pediatr Emerg Care. 2011;27:639–641.

44. Lammers AJ, de Porto AP, Bennink RJ, et al. Hyposplenism: comparison of different methods for determining splenic function. Am J Hematol. 2012;87:484–489.

45. National Primary Immunodeficiency Resource Center. Jeffrey Modell Foundation. Publications: 10 warning signs of a primary immunodeficiency. Available at: http://www.info4pi.org/aboutPI/index.cfm?option=aboutPI&content=warningsigns&Tkid=24&CFFID=465391&CFTOKEN=94554087. Accessed October 10, 2013.